- Amylyx Pharmaceuticals was removed in late June 2026 from multiple Russell equity indexes, while also reporting initial Phase 1 LUMINA data showing AMX0114 was generally well tolerated at the lowest dose in people living with ALS.
- The combination of broad index deletions and early but encouraging ALS safety data highlights how technical trading flows and pipeline progress can pull Amylyx’s story in different directions at the same time.
- Now we’ll examine how early Phase 1 LUMINA safety results for AMX0114 fit into and potentially reshape Amylyx’s broader investment narrative.
Find 44 companies with promising cash flow potential yet trading below their fair value.
Amylyx Pharmaceuticals Investment Narrative Recap
To own Amylyx today, you need to believe avexitide can clear its single pivotal Phase 3 LUCIDITY trial in post bariatric hypoglycemia and eventually support a first commercial franchise, while the broader pipeline adds longer term depth. The sweeping Russell index removals mainly affect trading technicals, not the underlying science or near term LUCIDITY readout, whereas the early AMX0114 LUMINA safety data modestly strengthens the case for Amylyx’s multiyear neurodegeneration ambitions.
The AMX0114 Phase 1 LUMINA update is the most relevant development here, because it keeps Amylyx’s ALS option in play at a time when the business is still loss making and dependent on pipeline progress. Showing no drug related serious adverse events at the lowest dose and advancing into higher dose cohorts supports the idea that Amylyx is not only tied to avexitide, which matters if LUCIDITY outcomes or PBH adoption end up more challenging than hoped.
Yet while AMX0114’s early safety profile is encouraging, investors should also be aware that...
Read the full narrative on Amylyx Pharmaceuticals (it's free!)
Amylyx Pharmaceuticals' narrative projects $107.8 million in revenue and $23.1 million in earnings by 2029. This implies an earnings increase of about $168 million from -$144.7 million today.
Uncover how Amylyx Pharmaceuticals' forecasts yield a $22.20 fair value, a 22% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts, who previously modeled revenue reaching about US$516,100,000 by 2029, lean heavily on avexitide’s PBH success and a smooth cash runway into 2028, while the recent index exits and LUMINA ALS update could eventually challenge or reinforce how you think about that reliance on a single pivotal readout and the company’s broader rare disease strategy.
Explore 2 other fair value estimates on Amylyx Pharmaceuticals - why the stock might be worth over 3x more than the current price!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Amylyx Pharmaceuticals research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Amylyx Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amylyx Pharmaceuticals' overall financial health at a glance.
Interested In Other Possibilities?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
- Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com